IP Verse

National Cancer Center competitive analysis

Loading summary...

Latest patents of National Cancer Center opposed by its competitors

Explore National Cancer Center's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 30, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3121274	Dec 18, 2019	Method For Predicting Responsiveness To Cancer Treatment Using P300-Inhibiting Compound	1

Latest publications and patents of National Cancer Center New

Explore the latest publications and patents granted to National Cancer Center, showcasing their recent innovations and technological advancements.

Last updated on: Oct 23, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of National Cancer Center
EP4293013	Aug 20, 2025	Novel Compound, Production Method Therefor, And Pharmaceutical Composition	Granted And Under Opposition
EP3121274	Dec 18, 2019	Method For Predicting Responsiveness To Cancer Treatment Using P300-Inhibiting Compound	Granted And Under Opposition
EP2848697	Jan 3, 2018	Method For Predicting Prognosis Of Renal Cell Carcinoma	No Opposition Filed Within Time Limit

Latest PTAB cases involving National Cancer Center

Discover the latest PTAB cases involving National Cancer Center, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing National Cancer Center with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 30, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
NATIONAL CANCER CENTER	-	1	-	-
CELLCENTRIC	1	-	-	-